Drug Profile
AC 0058 - ACEA Therapeutics
Alternative Names: AC 0058TA; AC-0058Latest Information Update: 31 Oct 2023
Price :
$50
*
At a glance
- Originator ACEA Biosciences
- Developer ACEA Therapeutics; Hangzhou ACEA Pharmaceutical Research
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autoimmune disorders
- No development reported Systemic lupus erythematosus
- Discontinued Rheumatoid arthritis
Most Recent Events
- 31 Oct 2023 Phase I development is ongoing USA (ACEA pharmaceuticals pipeline, October 2023)
- 31 Oct 2023 Phase-I clinical trials in Autoimmune disorders in China (PO) (ACEA pharmaceuticals pipeline, October 2023)
- 28 Dec 2021 No recent reports of development identified for phase-I development in Systemic-lupus-erythematosus in USA (PO, Capsule)